Clinical Trial Update: A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels [Phase 4]

View source ↗

Summary

Pfizer-sponsored Phase 4 trial to assess whether lowering LDL cholesterol below minimum target levels provides additional cardiovascular risk reduction; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Coronary Heart Disease
• Stroke

Snippet

Sponsor: Pfizer | Conditions: Cardiovascular Disease, Cerebrovascular Accident | Phase 4 | Status: COMPLETED